MA51413A - Utilisation de dérivés d'alcool alkylique de 1-phényl-2-pyridinyl pour le traitement de la fibrose kystique - Google Patents
Utilisation de dérivés d'alcool alkylique de 1-phényl-2-pyridinyl pour le traitement de la fibrose kystiqueInfo
- Publication number
- MA51413A MA51413A MA051413A MA51413A MA51413A MA 51413 A MA51413 A MA 51413A MA 051413 A MA051413 A MA 051413A MA 51413 A MA51413 A MA 51413A MA 51413 A MA51413 A MA 51413A
- Authority
- MA
- Morocco
- Prior art keywords
- phenyl
- treatment
- cystic fibrosis
- alkyl alcohol
- alcohol derivatives
- Prior art date
Links
- -1 1-PHENYL-2-PYRIDINYL Chemical class 0.000 title 1
- 201000003883 Cystic fibrosis Diseases 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17210827 | 2017-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51413A true MA51413A (fr) | 2021-04-28 |
Family
ID=60813721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051413A MA51413A (fr) | 2017-12-28 | 2018-12-19 | Utilisation de dérivés d'alcool alkylique de 1-phényl-2-pyridinyl pour le traitement de la fibrose kystique |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20210038575A1 (fr) |
| EP (1) | EP3732164A1 (fr) |
| BR (1) | BR112020012972A2 (fr) |
| MA (1) | MA51413A (fr) |
| WO (1) | WO2019129586A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61558B1 (sr) * | 2013-10-22 | 2021-04-29 | Chiesi Farm Spa | Kristalni oblik pde4 inhibitora |
| CN115466169B (zh) * | 2021-06-10 | 2024-03-26 | 中国医学科学院药物研究所 | 取代邻苯二酚醚类化合物及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2044023B1 (fr) | 2006-07-14 | 2011-01-19 | CHIESI FARMACEUTICI S.p.A. | Derivés d'alcools de 1-phényl-2-pyridynyl alkylène en tant qu'inhibiteurs de phosphodiestérase |
| EP2022783A1 (fr) | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | Dérivés d'alcools 1-phényl-2-pyridinylalkyliques en tant qu'inhibiteurs de la phosphodiestérase |
| EP2216327A1 (fr) | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoate de (1-Phenyl-2-Pyridin-4-yl)ethyle en tant qu'inhibiteurs de phosphodiestérase |
| EP2928869B1 (fr) * | 2012-12-05 | 2019-02-20 | Chiesi Farmaceutici S.p.A. | Dérivés d'alcool 1-phényl-2-pyridinyl alkylique en tant qu'inhibiteurs de phosphodiestérase |
| EP3142748B1 (fr) | 2014-05-15 | 2019-09-11 | Celgene Corporation | Utilisation d'inhibiteurs de pde4 et de leurs combinaisons pour le traitement de la fibrose kystique |
-
2018
- 2018-12-19 MA MA051413A patent/MA51413A/fr unknown
- 2018-12-19 EP EP18836234.7A patent/EP3732164A1/fr not_active Withdrawn
- 2018-12-19 WO PCT/EP2018/085965 patent/WO2019129586A1/fr not_active Ceased
- 2018-12-19 BR BR112020012972-0A patent/BR112020012972A2/pt not_active Application Discontinuation
- 2018-12-19 US US16/769,074 patent/US20210038575A1/en not_active Abandoned
-
2022
- 2022-03-31 US US17/709,591 patent/US20220218678A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020123677A3 (fr) | 2022-01-28 |
| RU2020123677A (ru) | 2022-01-28 |
| EP3732164A1 (fr) | 2020-11-04 |
| WO2019129586A1 (fr) | 2019-07-04 |
| US20220218678A1 (en) | 2022-07-14 |
| BR112020012972A2 (pt) | 2020-11-24 |
| US20210038575A1 (en) | 2021-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51739A (fr) | Compositions pharmaceutiques pour le traitement de la fibrose kystique | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| EP3645039A4 (fr) | Utilisation d'anticorps anti-fam19a5 pour le traitement de la fibrose | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| EP3448875A4 (fr) | Compositions pour le traitement de maladies | |
| EP3448987A4 (fr) | Compositions pour le traitement de maladies | |
| EP3558313A4 (fr) | Substances pour le traitement d'affections liées à la stéatose hépatique | |
| EP3442488A4 (fr) | Compositions pour l'application topique de composés | |
| MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
| EP3013345A4 (fr) | Composés pour le traitement d'une amyotrophie spinale | |
| EP3504187A4 (fr) | Utilisation de la pridopidine pour le traitement du déclin fonctionnel | |
| MA51139A (fr) | Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer | |
| EP3634426A4 (fr) | Compositions pour le traitement d'une fibrose | |
| EP3454896A4 (fr) | Dérivés hétérocycliques pour le traitement de rsv | |
| EP3352749A4 (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| MA44737A (fr) | Compositions pour le traitement de troubles liés à l'hyperkératose | |
| EP2968321A4 (fr) | Composés pour le traitement de maladies de fibrose | |
| EP3378484A4 (fr) | Composition pharmaceutique pour le traitement de la fibrose cardiaque | |
| EP3898991A4 (fr) | Administration périnéale de résinifératoxine pour le traitement de la douleur maladaptative | |
| EP3630080A4 (fr) | Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer | |
| EP3805216A4 (fr) | Composés pour le traitement ou la prévention de maladies hépatiques | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| EP3773221A4 (fr) | Traitement pour l'hydrocéphalie | |
| EP3302488A4 (fr) | Nouvelle utilisation de dérivés aryl-quinoléine comme inhibiteurs de l'imitation de facteurs vasculogènes | |
| MA49140A (fr) | Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques |